Form 4: Aldeyra Therapeutics Director Ben Bronstein Acquires Stock Options
SEC Form 4 Filing
Director Ben Bronstein acquired stock options in Aldeyra Therapeutics, Inc. on June 4, 2024.
Summary
- Ben Bronstein, a director of Aldeyra Therapeutics, Inc., acquired stock options on June 4, 2024.
- The options are exercisable at a price of $4.09.
- Bronstein acquired 40,282 options related to his board service, 2,604 options related to his Audit Committee service, and 2,778 options related to his Nominating/Corporate Governance Committee service.
- The options vest one year from the grant date, contingent upon continuous service.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock option grants, which is neutral in sentiment.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to incentivize and align the interests of directors with those of shareholders.
Stakeholder Impact
- The stock option grants align the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/04/2024 | Date of stock option acquisition |
| 06/03/2034 | Expiration date of stock options |
| 06/06/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.